Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/16/2017 08/17/2017 08/18/2017 08/21/2017 08/22/2017 Date
21.55(c) 21.8(c) 21.9(c) 21.85(c) 22.8 Last
310 548 685 607 421 807 320 568 172 793 Volume
+1.65% +1.16% +0.46% -0.23% +4.35% Change
More quotes
Financials ($)
Sales 2017 568 M
EBIT 2017 81,1 M
Net income 2017 29,0 M
Debt 2017 184 M
Yield 2017 -
Sales 2018 465 M
EBIT 2018 15,0 M
Net income 2018 -5,23 M
Debt 2018 247 M
Yield 2018 -
P/E ratio 2017 45,52
P/E ratio 2018
EV / Sales2017 2,12x
EV / Sales2018 2,72x
Capitalization 1 019 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
08/10 ACORDA THERAPEUTICS : Researchers Submit Patent Application, "Sustained Release ..
08/08 ACORDA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
08/07 ACORDA THERAPEUTICS,INC. (NASDAQ : ACOR) Files An 8-K Regulation FD Disclosure
08/03 ACORDA THERAPEUTICS : Provides Financial and Pipeline Update for Second Quarter ..
07/27 ACORDA THERAPEUTICS, INC. (NASDAQ : ACOR) reported earnings of $0.29 per share m..
07/27 ACORDA THERAPEUTICS,INC. (NASDAQ : ACOR) Files An 8-K Results of Operations and ..
07/27 ACORDA THERAPEUTICS INC : Results of Operations and Financial Condition, Financi..
07/27 ACORDA THERAPEUTICS : reports 2Q loss
07/27 ACORDA THERAPEUTICS : Provides Financial and Pipeline Update for Second Quarter ..
07/13 ACORDA THERAPEUTICS : Second Quarter 2017 Update Webcast/Conference Call Schedul..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/19ClariVest Asset Management LLC Sells 32 Shares of Acorda Therapeutics, Inc. $.. 
08/11Acorda Therapeutics investor calls for company to explore sale
1
08/08$ACOR (+0.0% pre) Acorda Stiff-Arms Investor's Demand for Sale - TheStreet
1
08/08Scopia Capital Management Takes a Stake in Acorda Therapeutics  
08/07Activists Gonna Activate: Hedge Funds Send Letters To Acorda, Taubman Centers.. 
More tweets
Qtime:19
News from SeekingAlpha
07/30 Acorda Therapeutics, Inc. 2017 Q2 - Results - Earnings Call Slides
07/30 Acorda Therapeutics' (ACOR) CEO Ron Cohen on Q2 2017 Results - Earnings Call ..
07/28 Acorda Slump Offers Investment Opportunity
07/27 Acorda Investors Are Holding Their Breath
07/27 Acorda Therapeutics misses by $0.19, misses on revenue
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Technical analysis trends ACORDA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 23,8 $
Spread / Average Target 9,1%
EPS Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
Andrew R. Blight Chief Scientific Officer
Anthony O. Caggiano Vice President-Research & Development
Richard P. Batycky Chief Technology Officer
Burkhard Blank Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS INC16.22%1 019
AMGEN14.42%122 067
CELGENE CORPORATION10.28%99 867
GILEAD SCIENCES0.70%94 170
REGENERON PHARMACEUTICALS27.48%50 145
VERTEX PHARMACEUTICALS101.07%37 346